Today’s Stock Market Recommendations By CapitalHeight

            

         Nifty volatile; pharma, infra, FMCG stocks decline

Nifty is likely to stay around 7,600 level in the near-term, adding that this has been the largest up-move among expiries in recent times “The options market data tells us that Nifty should perhaps expire at around 7,600 levels.” However, he believes that these levels are still overvalued. “It might go there (near the 7600 level) from a technical perspective, but it doesn’t seem to have the fundamental strength,” he adds. Drug firm Aurobindo Pharma has received final approval from USFDA to manufacture and market Rivastigmine Tart rate Capsules USP, used for the treatment of dementia disease, in the American market. "The company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Rivastigmine Tart rate Capsules USP, 1.5 mg, 3 mg, 4.5 mg and 6 mg," Aurobindo Pharma said in a BSE filing. The company said this product is expected to be launched in the first quarter of next fiscal.  Also read - Govt, RBI taking tough action to recover bank dues..

For More Updates visit our site

www.capitalheight.com/stock-tips.php

Or call@ 0731-6615050; +91 9993066624, 8962429710